The invention relates to a system (4) for estimating a fertility status of a woman, particularly for determining a conception probability of a woman, the system (4) comprising:—A wearable device (2A, 2B), comprising at least one sensor (201, 203, 204) configured to record at least one physiological signal from a woman wearing the wearable device (2A, 2B) and to generate sensor data from the at least one physiological signal, wherein the wearable device (2A, 2B) is configured and arranged to provide the sensor data to—An evaluation system (1) configured and arranged to receive and process the sensor data from the wearable device (2A, 2B), wherein the evaluation system (1) is further configured and arranged to classify the sensor data into at least a first group and a second group, wherein the first group is associated to sensor data indicative of a woman having a high fertility status and wherein the second group is associated to sensor data indicative of a woman having a low fertility status.

An electronic system for non-invasive monitoring of estrogen of a female human comprises a wearable device (1) and a processor (13, 30, 40). The wearable device (1) includes a first sensor system (101) configured to be worn in contact with the skin of the female human and to determine a level of perfusion of the female human. The processor (13, 30, 40) is configured to receive and store the level of perfusion of the female human from the first sensor system (101) for a respective point in time. The processor (13, 30, 40) is further configured to determine a change in the level of perfusion of the female human, using the levels of perfusion of the female human stored for a plurality of respective points in time. Furthermore, the processor (13, 30, 40) is configured to detect a change in estrogen level of the female human based on the change in the level of perfusion of the female human.

An electronic system for non-invasive monitoring of estrogen of a female human comprises a wearable device and a processor. The wearable device includes a first sensor system configured to be worn in contact with the skin of the female human and to determine a level of perfusion of the female human. The processor is configured to receive and store the level of perfusion of the female human from the first sensor system for a respective point in time. The processor is further configured to determine a change in the level of perfusion of the female human, using the levels of perfusion of the female human stored for a plurality of respective points in time. Furthermore, the processor is configured to detect a change in estrogen level of the female human based on the change in the level of perfusion of the female human.

Provided herein are systems and methods that use an electrochemical aptamer-based (EAB) biosensor to detect a plurality of hormone and/or analyte that can be used for fertility and pregnancy monitoring.

An electronic system for determining a time of the temperature nadir of a female human during the menstrual cycle comprises a wearable device (1) that includes a first sensor system (104), configured to determine a temperature of the female human, and a second sensor system (101, 102, 103), configured to determine one or more further physiological parameters of the female human. The electronic system further comprises a processor (13, 30, 40), configured to determine a detected starting point of the fertility phase of the female human, using the one or more further physiological parameters of the female human. The processor (13, 30, 40) is further configured to detect the temperature nadir as a temporary decrease in the temperature, using the detected starting point of the fertility phase of the female human. The time of the temperature nadir is used as an indicator of the time of ovulation and peak oestrogen level.

A non-invasive and accurate vagina evaluation device and uterine evaluation devices are provided that measure the receptivity (uterine implantation capacity) of the mother's body to a fertilized egg implanting itself into the uterus. A first vagina evaluation device includes: a main body stretchable and expandable after insertion into a vagina, followed by air injection thereinto; four electrodes brought into contact with the vagina wall as the main body expands and stretches; and fixation means configured to fix the interval of arrangement of the electrodes. Second and third uterine evaluation device include: a flexible and rod-shaped main body for insertion into a uterine cavity; and four or two impedance electrodes arranged with a predetermined interval therebetween in an insertion direction of the main body and brought into contact with an endometrium of the uterine cavity to measure a uterine endometrial impedance generated between the endometrium and each of the electrodes.

A vaginal device configured to be inserted in a vagina of a user, the vaginal device comprising: a body comprising at least two electrodes configured to measure a fertility-related parameter of the user; a power source configured to provide power to the device; and an electrical system operably connected to the power source, the electrical system operably connected to one or more of the electrodes, the electrical system configured to switch one or more of the electrodes between charging and measuring functions.

The device and method for calculating and displaying to a user a predicted fertility window, start and end date, and conception planning guide for the user is presented. The device and method include a vaginal sensor device having a plurality of sensors to collect measurements related to vaginal and cervical parameters that are important to the conception cycle. The device and method are customized for an individual user through the input by a user of menstrual cycle timing and duration, ovulation data, temperature data, and other data that are personal to the user. The system utilizes all collected sensor measurements, input user data, and historical data to provide a predicted fertility window, including predicted start and end dates, for the user.

A method of sampling and testing for SARS-COV-2 virus in nasal and nasopharyngeal fluid using a plurality of microfluidic channels with a plurality of integrated electrodes in the microfluidic channels to detect the virus. In one example embodiment, a plurality of antibodies are fixed on a surface of at least one electrode by positive dielectrophoresis that increases the sensitivity of detection. Viral antigens bind to the antibodies separating from the fluid thereby signally that the virus is present as evidenced by the detection of the antigens. Sampling by microfluidic channels is more comfortable to a patient because microfluidic channels are soft, flexible and narrow compared to swabs. Another example embodiment of a method using microfluidic channels for collecting tears or saliva to determine blood glucose levels using a smartphone that has been modified to incorporate external filters quantitate glucose levels is also described.

Devices, systems and related methods for direct and in-vivo monitoring and stimulation of the endometrial cavity include a plurality of sensing modalities incorporated on a set of flexible conductive filaments that allows its insertion in an endometrial cavity through the vagina. The flexible set of conductive filaments is in direct contact with the endometrium to maximize recording sensitivity and acquire direct readings, which correspond to the functionality of the endometrium and/or electrically stimulate endometrial peristalsis in a controlled manner. The same electrodes can be used for a controlled stimulation to strengthen weakened muscle tissue before and after medical and surgical interventions on the uterus, to reset to normal contractility. The methods and systems disclosed herein can be used to improve the chances of success for artificial insemination, including in-vitro fertilization, embryo transfer, and intrauterine insemination, diagnostic tests, and may further improve the overall understanding of endometrial functionality.